Coherus BioSciences Inc (CHRS) stock news · rev $42.2M
Coherus BioSciences Inc (CHRS) is a biotechnology company listed on US.
This CHRS news page leads with what Coherus BioSciences Inc filed — not a scraped headline mill.
No cached 8-K sentence for CHRS yet. We will not pad this page with generic market recap.
Latest reported CHRS revenue for 2025-12-31 was $42.2M. Net income was $168.0M. Revenue was down 84.2% from 2024-12-31 to 2025-12-31. CHRS currently screens at market cap $223.7M.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the CHRS stock page; for the tape open the quote page.
CHRS stock news FAQ
What are CHRS's latest revenue and net income?
Latest cached Coherus BioSciences Inc (CHRS) revenue for Dec 31, 2025 was $42.2M. Net income was $168.0M. Statements: https://lician.com/financials/chrs
How did CHRS revenue change from the prior cached period?
Cached Coherus BioSciences Inc (CHRS) revenue was down 84.2% from $267.0M (Dec 31, 2024) to $42.2M (Dec 31, 2025). Statements: https://lician.com/financials/chrs
What is CHRS's market cap?
Coherus BioSciences Inc (CHRS) market cap is $223.7M on the latest cached fundamentals snapshot.
What kind of company is CHRS?
Coherus BioSciences Inc (CHRS) is a biotechnology company listed on US.
Where is CHRS stock news listed?
Cached stock news for Coherus BioSciences Inc (CHRS) is listed at https://lician.com/news/chrs. Filings: https://lician.com/sec/chrs
Not investment advice.